Abstract
AbstractDeep learning models based on medical images have made significant strides in predicting treatment outcomes. However, previous methods have primarily concentrated on single time-point images, neglecting the temporal dynamics and changes inherent in longitudinal medical images. Thus, we propose a Transformer-based longitudinal image analysis framework (LOMIA-T) to contrast and fuse latent representations from pre- and post-treatment medical images for predicting treatment response. Specifically, we first design a treatment response- based contrastive loss to enhance latent representation by discerning evolutionary processes across various disease stages. Then, we integrate latent representations from pre- and post-treatment CT images using a cross-attention mechanism. Considering the redundancy in the dual-branch output features induced by the cross-attention mechanism, we propose a clinically interpretable feature fusion strategy to predict treatment response. Experimentally, the proposed framework outperforms several state-of-the-art longitudinal image analysis methods on an in-house Esophageal Squamous Cell Carcinoma (ESCC) dataset, encompassing 170 pre- and post-treatment contrast-enhanced CT image pairs from ESCC patients underwent neoadjuvant chemoradiotherapy. Ablation experiments validate the efficacy of the proposed treatment response-based contrastive loss and feature fusion strategy. The codes will be made available athttps://github.com/syc19074115/LOMIA-T.
Publisher
Cold Spring Harbor Laboratory
Reference28 articles.
1. Predicting treatment response from longitudinal images using multi-task deep learning[J];Nature communications,2021
2. Deep learningassisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases[J];International Journal of Cancer,2021
3. Deep learning of longitudinal mammogram examinations for breast cancer risk prediction[J];Pattern recognition,2022
4. Neoadjuvant chemora-diotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): longterm results of a randomised controlled trial;Lancet Oncol,2015
5. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer;Br. J. Surg,2013